Sanjay Kumar

About

Currently, I am a research fellow at the National University of Singapore, where I investigate proteostasis mechanisms in aging and age-related disorders using advanced cellular and animal models. My work aims to uncover molecular pathways that delay aging and promote healthy longevity, contributing to transformative research on extending healthspan and addressing age-associated health challenges.
Previously, as a research associate at the University of Massachusetts Medical School, I explored the molecular underpinnings of neurodegeneration, focusing on phase separation in FUS-associated ALS. At Mayo Clinic Florida, my research centered on the cellular and molecular mechanisms driving Parkinson’s disease and related neurodegenerative conditions.
My experience also includes translational research at SHC Shine Biotech Pvt. Ltd., developing rapid, affordable point-of-care diagnostics for clinical applications. Earlier, as a Junior Research Fellow at Jiwaji University, I studied the role of glial cells in brain development and injury response.
During my graduate studies, I characterized novel Parkinson’s disease-linked α-synuclein mutants, elucidating their aggregation properties and the modulatory role of DJ-1 in α-synuclein pathology.
My future goal is to advance the field of aging and healthy longevity by developing innovative diagnostics and interventions targeting neurodegenerative diseases, with potential applications in both human health and longevity research.

Employment

• National University of Singapore Research Fellow
  2023 - Present
• University of Massachusetts Chan Medical School Research Associate
  2022 - 2033
• Mayo Clinic Neurodegeneration
  2021 - 2022

Education

• Regional Centre for Biotechnology PhD
  2014 - 2020

Projects & Funding

Projects & funding information is unavailable.

Publications (7)

• Towards Healthy Longevity: Comprehensive Insights from Molecular Targets and Biomarkers to Biological Clocks
  International Journal of Molecular Sciences 2024 DOI: 10.3390/ijms25126793
  +Save
• Ellagic Acid Inhibits α-Synuclein Aggregation at Multiple Stages and Reduces Its Cytotoxicity
  ACS Chemical Neuroscience 2021 DOI: 10.1021/acschemneuro.1c00001
  +Save
• Amyloid aggregates of the deubiquitinase OTUB1 are neurotoxic, suggesting that they contribute to the development of Parkinson's disease
  Journal of Biological Chemistry 2020 DOI: 10.1074/jbc.ra119.009546
  +Save
• Partially oxidized DJ-1 inhibits α-synuclein nucleation and remodels mature α-synuclein fibrils in vitro
  Communications Biology 2019 DOI: 10.1038/s42003-019-0644-7
  +Save
• Extracellular α-Synuclein Disrupts Membrane Nanostructure and Promotes S-Nitrosylation-Induced Neuronal Cell Death
  Biomacromolecules 2018 DOI: 10.1021/acs.biomac.7b01727
  +Save
• Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced α-Synuclein Fibrillation and Cytotoxicity
  ACS Chemical Neuroscience 2018 DOI: 10.1021/acschemneuro.6b00430
  +Save
• S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation
  Scientific Reports 2017 DOI: 10.1038/srep44558
  +Save